FMP 010 vaccine

Drug Profile

FMP 010 vaccine

Alternative Names: FMP010/AS01B - GlaxoSmithKline

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; Kenya Medical Research Institute; U.S. Army Medical Materiel Development Activity; United States Agency for International Development; Walter Reed Army Institute of Research
  • Class Protein-vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 01 Jun 2013 Discontinued - Phase-I for Malaria (Prevention) in Kenya, USA (IM)
  • 01 Jun 2011 No development reported - Phase-I for Malaria (Prevention) in Kenya, USA (IM)
  • 01 Apr 2008 Phase-I clinical trials in Malaria (Prevention) in Kenya, USA (IM) (NCT00666380; NCT02458092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top